Abstracts tagged "immune response and vaccines"

Abstract Number: 1182 • 2017 ACR/ARHP Annual Meeting
Autoantibody Profiling in Prostvac and Ipilimumab Treated Prostate Cancer Patients Reveals Potential Biomarkers of Immune-Related Adverse Events
Petra Budde¹, Jennifer Marte², Hans-Dieter Zucht¹, Saurabh Bhandari¹, Manuel Tuschen¹, Peter Schulz-Knappe¹, James Gulley², Christopher Heery³, Ravi Madan² and Jeffrey Schlom², ¹Protagen AG, Dortmund, Germany, ²National Cancer Institute, National Institutes of Health, Bethesda, MD, ³Bavarian Nordic, Inc., Morrisville, NC
Background/Purpose: Autoantibodies (AAB) targeting self-antigens can be found in two clinically and immunologically opposing diseases, autoimmune diseases and cancer. While in autoimmune diseases, the immune…
Abstract Number: 1381 • 2016 ACR/ARHP Annual Meeting
Humoral Immune Response and Cytokine Profile after a Booster Dose with Tdap Vaccine in Juvenile Systemic Lupus Erythematosus and Controls
Octavio Peracchi¹, Aline Nicacio², Fernanda Spina³, Juliana Yamada³, Brunna Alvarenga³, Maria Isabel Pinto³ and Maria Teresa Terreri⁴, ¹Pediatric Rheumatology, Federal University of Sao Paulo, Department of Pediatrics, Sao Paulo, Brazil, Sao Paulo, Brazil, ²Pediatric Rheumatology Unit, Department of Pediatrics, Federal University of Sao Paulo, Sao Paulo, Brazil, Sao Paulo, Brazil, ³Federal University of Sao Paulo, Department of Pediatrics, Sao Paulo, Brazil, Sao Paulo, Brazil, ⁴Pediatric Rheumatology Unit, Federal University of São Paulo, São Paulo, Brazil
Background/Purpose: Pertussis cases have increased worldwide and knowledge on immune response and cytokine profile after adult Tdap vaccine is scarce. This study evaluated the humoral…
Abstract Number: L23 • 2014 ACR/ARHP Annual Meeting
Humoral Immune Response to Pneumococcal Polysaccharide Vaccine in SLE Patients on Immunosuppressive Therapy: Assessment of Serotypes without Protective Antibody Levels
Rodrigo Poubel V. Rezende¹, Francinne M. Ribeiro¹, Luis Eduardo C. Andrade², Carlos Roberto M. Gayer³, Elisa M. N. Albuquerque¹ and Evandro Mendes Klumb¹, ¹Rheumatology, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, ²Fleury Laboratories, Sao Paulo, Brazil, ³Department of Biochemistry, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil
Background/Purpose: Previous works assessing antibody response to pneumococcal polysaccharide vaccine (PPV) in systemic lupus erythematosus (SLE) relied exclusively on the quantitative increase in antibody titers…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].